Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates

Stock Information for Inovio Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inovio Pharmaceuticals Inc.

INOVIO Announces Pricing of $25 Million Public Offering
INOVIO Announces Proposed Public Offering
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
INOVIO to Present at Upcoming Scientific and Investor Conferences
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
INOVIO to Present at Upcoming Scientific Conferences
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.